STAT+: The biotech news you need to read today

STAT PlusNewsletterThe Readout The biotech news you need to read today A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout Manage alerts for this article Email this article Share this article By STAT Staff and Meghana KeshavanMay 8, 2026 Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Capricor Therapeutics is mounting a legal fight against a partner over its promising Duchenne therapy, there’s new evidence that scientific creativity calcifies with age, and STAT’s Alex Hogan and Lizzy Lawrence share firsthand accounts from FDA officials who decided the agency was no longer a place they could stay.Advertisement Capricor sues partner over Duchenne therapy launch Capricor Therapeutics is suing its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, arguing the companies botched launch preparations for deramiocel, the biotech’s closely watched Duchenne muscular dystrophy cell therapy. Capricor says the companies also created a pricing structure that could make the treatment financially inaccessible for many patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints STAT Staff Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout May 7, 2026 STAT Plus: FDA revisits a rare cancer treatment it rejected a few months ago Biotech May 7, 2026 STAT Plus: FDA to reconsider treatment for rare cancer after its surprise rejection Advertisement Biotech May 7, 2026 STAT Plus: Next-gen Duchenne drug from Entrada disappoints Adam's Biotech Scorecard May 7, 2026 STAT Plus: Color me skeptical: Drinking gold is not an ALS cure Biotech May 7, 2026 STAT Plus: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B Subscriber Picks